| Features: chemotherapy drug that inhibits DNA topoisomerase I |
| Topotecan — Semisynthetic camptothecin analogue and conventional cytotoxic chemotherapy drug that inhibits DNA topoisomerase I (TOP1). Topotecan stabilizes the transient TOP1-DNA cleavage complex and prevents religation of single-strand DNA breaks. During DNA replication, these trapped complexes can generate lethal double-strand DNA damage and trigger cell death. Drug class: Conventional chemotherapy / topoisomerase I inhibitor / camptothecin analogue. Primary cancer uses: Used clinically in selected ovarian cancer, small-cell lung cancer, and cervical cancer settings. It is also investigated in additional solid and hematologic malignancies. Typical mechanisms: TOP1 inhibition ↑; TOP1-DNA cleavage complexes ↑; DNA single-strand breaks ↑; replication-associated double-strand DNA breaks ↑; replication stress ↑; S-phase cytotoxicity ↑; apoptosis ↑; proliferation ↓. Typical cancer direction: Anticancer activity is associated with TOP1 trapping and DNA damage ↑, leading to tumor-cell proliferation ↓ and cell death ↑. Important toxicities: Myelosuppression is a major dose-limiting toxicity, particularly neutropenia, anemia, and thrombocytopenia. Recommended abbreviation: Topotecan; TPT is used in some literature but should be used cautiously because it is not unique. Brand name: Hycamtin. |
| 9022- | Phyco, | TPT, | Phycocyanin induces apoptosis and enhances the effect of topotecan on prostate cell line LNCaP |
| - | in-vitro, | Pca, | LNCaP |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:527 Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid